Pregnancy associated alpha2-glycoprotein in post-menopausal women receiving hormone replacement therapy.
Serum pregnancy associated alpha2-glycoprotein (P.A.G.) concentrations were measured in a group of post-menopausal women receiving hormone replacement therapy. The P.A.G. concentrations increased from a mean basal level of 48.1 mug/ml (range 20.6--104.4 mug/ml) to a maximum after six months therapy of 359 mug/ml (range 82--1290 mug/ml). This represents a mean increase of 647%. Two months after cessation of therapy the P.A.G. concentrations decreased but the mean level (60.3 mug/ml) was still significantly higher than the pre-treatment level. There was a significant correlation between the pre-treatment P.A.G. concentrations and the levels after six months of therapy. These findings may be of relevance to the use of P.A.G. determinations in the monitoring of malignant disease.
D000328:Adult; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D008593:Menopause; D008598:Menstruation; D008656:Mestranol / Q000627:therapeutic use*; D008875:Middle Aged; D009640:Norethindrone / Q000627:therapeutic use*; D011247:Pregnancy; D013997:Time Factors
D006023:Glycoproteins; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D008656:Mestranol; D009640:Norethindrone